FMP
Histogen Inc.
HSTO
NASDAQ
Inactive Equity
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.02 USD
0 (0%)
HSTO Financial Statements
Year
2022
2021
2020
2019
Total Revenue
3.77M
919k
2.06M
11.3M
Cost of Revenue
0
220k
968k
2.21M
Gross Profit
3.77M
699k
1.09M
9.09M
Operating Expenses
14.41M
16.16M
12.8M
10.16M
Research and Development
5.02M
8.47M
6.22M
4.09M
Selling, General & Administrative Expenses
9.39M
7.8M
6.59M
6.21M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
9.39M
7.8M
6.59M
6.21M
Other Expenses
0
-113k
105k
-150k
Operating Income
-10.64M
-15.46M
-11.71M
905k
Total Other Income/Expenses Net
-1k
448k
-7.1M
-1.93M
Income Before Tax
-10.64M
-15.01M
-18.82M
-3M
Income Tax
0
-604k
6.96M
1.9M
Net Income
-10.62M
-14.4M
-25.77M
-4.9M
Basic EPS
-3.46
-7.51
-57.16
-8.29
EPS Diluted
-3.46
-7.51
-57.16
-8.29
Basic Average Shares
3.21M
1.92M
450.92k
590.69k
Diluted Average Shares
3.21M
1.92M
450.92k
590.69k
EBITDA
-10.5M
-14.9M
-18.66M
-2.86M
All figures are in USD.
